CMOPF Quote, Financials, Valuation and Earnings

GH Research Plc has a net margin of -- compared to Cosmo Pharmaceuticals NV's net margin of --. Cosmo Pharmaceuticals NV's return on equity of 15.06% beat GH Research Plc's return on equity of -16.86%.

Cosmo Pharmaceuticals NV has a consensus price target of --, signalling downside risk potential of --. On the other hand GH Research Plc has an analysts' consensus of $33.48 which suggests that it could grow by 114.71%. Given that GH Research Plc has higher upside potential than Cosmo Pharmaceuticals NV, analysts believe GH Research Plc is more attractive than Cosmo Pharmaceuticals NV.

Cosmo Pharmaceuticals NV has a beta of 0.402, which suggesting that the stock is 59.833% less volatile than S&P 500. In comparison GH Research Plc has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cosmo Pharmaceuticals NV has a quarterly dividend of $2.34 per share corresponding to a yield of 2.85%. GH Research Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cosmo Pharmaceuticals NV pays 24.72% of its earnings as a dividend. GH Research Plc pays out -- of its earnings as a dividend. Cosmo Pharmaceuticals NV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cosmo Pharmaceuticals NV quarterly revenues are --, which are smaller than GH Research Plc quarterly revenues of --. Cosmo Pharmaceuticals NV's net income of -- is lower than GH Research Plc's net income of -$14M. Notably, Cosmo Pharmaceuticals NV's price-to-earnings ratio is 38.26x while GH Research Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cosmo Pharmaceuticals NV is 13.09x versus -- for GH Research Plc. Usually stocks with elevated PS ratios are considered overvalued.

Iterum Therapeutics Plc has a net margin of -- compared to Cosmo Pharmaceuticals NV's net margin of -2302.31%. Cosmo Pharmaceuticals NV's return on equity of 15.06% beat Iterum Therapeutics Plc's return on equity of --.

Cosmo Pharmaceuticals NV has a consensus price target of --, signalling downside risk potential of --. On the other hand Iterum Therapeutics Plc has an analysts' consensus of $5.50 which suggests that it could grow by 2494.34%. Given that Iterum Therapeutics Plc has higher upside potential than Cosmo Pharmaceuticals NV, analysts believe Iterum Therapeutics Plc is more attractive than Cosmo Pharmaceuticals NV.

Cosmo Pharmaceuticals NV has a beta of 0.402, which suggesting that the stock is 59.833% less volatile than S&P 500. In comparison Iterum Therapeutics Plc has a beta of 2.969, suggesting its more volatile than the S&P 500 by 196.931%.

Cosmo Pharmaceuticals NV has a quarterly dividend of $2.34 per share corresponding to a yield of 2.85%. Iterum Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cosmo Pharmaceuticals NV pays 24.72% of its earnings as a dividend. Iterum Therapeutics Plc pays out -- of its earnings as a dividend. Cosmo Pharmaceuticals NV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cosmo Pharmaceuticals NV quarterly revenues are --, which are smaller than Iterum Therapeutics Plc quarterly revenues of $390K. Cosmo Pharmaceuticals NV's net income of -- is lower than Iterum Therapeutics Plc's net income of -$9M. Notably, Cosmo Pharmaceuticals NV's price-to-earnings ratio is 38.26x while Iterum Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cosmo Pharmaceuticals NV is 13.09x versus 19.91x for Iterum Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.

Jazz Pharmaceuticals Plc has a net margin of -- compared to Cosmo Pharmaceuticals NV's net margin of 22.33%. Cosmo Pharmaceuticals NV's return on equity of 15.06% beat Jazz Pharmaceuticals Plc's return on equity of -9.16%.

Cosmo Pharmaceuticals NV has a consensus price target of --, signalling downside risk potential of --. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $219.40 which suggests that it could grow by 27.42%. Given that Jazz Pharmaceuticals Plc has higher upside potential than Cosmo Pharmaceuticals NV, analysts believe Jazz Pharmaceuticals Plc is more attractive than Cosmo Pharmaceuticals NV.

Cosmo Pharmaceuticals NV has a beta of 0.402, which suggesting that the stock is 59.833% less volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.260, suggesting its less volatile than the S&P 500 by 73.986%.

Cosmo Pharmaceuticals NV has a quarterly dividend of $2.34 per share corresponding to a yield of 2.85%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cosmo Pharmaceuticals NV pays 24.72% of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend. Cosmo Pharmaceuticals NV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cosmo Pharmaceuticals NV quarterly revenues are --, which are smaller than Jazz Pharmaceuticals Plc quarterly revenues of $1.1B. Cosmo Pharmaceuticals NV's net income of -- is lower than Jazz Pharmaceuticals Plc's net income of $251.4M. Notably, Cosmo Pharmaceuticals NV's price-to-earnings ratio is 38.26x while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cosmo Pharmaceuticals NV is 13.09x versus 2.53x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

Prothena Corp. Plc has a net margin of -- compared to Cosmo Pharmaceuticals NV's net margin of -102804.76%. Cosmo Pharmaceuticals NV's return on equity of 15.06% beat Prothena Corp. Plc's return on equity of -66.9%.

Cosmo Pharmaceuticals NV has a consensus price target of --, signalling downside risk potential of --. On the other hand Prothena Corp. Plc has an analysts' consensus of $20.50 which suggests that it could grow by 127.27%. Given that Prothena Corp. Plc has higher upside potential than Cosmo Pharmaceuticals NV, analysts believe Prothena Corp. Plc is more attractive than Cosmo Pharmaceuticals NV.

Cosmo Pharmaceuticals NV has a beta of 0.402, which suggesting that the stock is 59.833% less volatile than S&P 500. In comparison Prothena Corp. Plc has a beta of -0.113, suggesting its less volatile than the S&P 500 by 111.323%.

Cosmo Pharmaceuticals NV has a quarterly dividend of $2.34 per share corresponding to a yield of 2.85%. Prothena Corp. Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cosmo Pharmaceuticals NV pays 24.72% of its earnings as a dividend. Prothena Corp. Plc pays out -- of its earnings as a dividend. Cosmo Pharmaceuticals NV's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cosmo Pharmaceuticals NV quarterly revenues are --, which are smaller than Prothena Corp. Plc quarterly revenues of $21K. Cosmo Pharmaceuticals NV's net income of -- is lower than Prothena Corp. Plc's net income of -$21.6M. Notably, Cosmo Pharmaceuticals NV's price-to-earnings ratio is 38.26x while Prothena Corp. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cosmo Pharmaceuticals NV is 13.09x versus 50.14x for Prothena Corp. Plc. Usually stocks with elevated PS ratios are considered overvalued.